1. Brazil Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ourofino S.A.

Ourofino S.A.

29.42
BRL
-0.73
(-2.42%)
4.39EPS
6.49P/E
1.53BMarket Cap
Nov 05Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.07
9.9
8.46
9.37
10.92
11.48
13.53
16.79
19.36
17.54
19.06
22.78
25.39
Basic EPS, GAAP
0.7
1.28
-0.1
0.71
1.28
0.86
1.66
2.11
2.43
-0.93
2.5
4.13
4.39
Free Cash Flow per Basic Share
-0.54
-0.77
-0.8
1.25
-0.1
0.08
1.62
-0.37
0.36
2.65
0.54
0.98
3.73
Dividend per Share
- -
0.24
0.3
- -
0.2
0.3
0.2
0.66
0.62
0.44
0.34
0.65
- -
Book Value per Share
6.12
7.05
6.98
7.52
8.45
9.13
10.39
11.93
13.69
12.82
14.07
14.82
15.38
Tangible Book Value per Share
4.89
5.59
5.36
5.92
6.71
7.4
9.02
10.6
11.71
11.1
12.08
12.85
13.92
Basic Weighted Avg Shares
54
54
54
54
54
54
54
54
54
54
54
54
54
Sales/Revenue/Turnover
327
534
457
505
589
620
730
905
1,041
943
1,025
1,225
1,365
Operating Margin (%)
18.99
17.98
3.99
13.22
17.77
12.63
17.12
16.32
16.87
10.96
18.85
19.94
20.86
Depreciation Expense
11
20
22
25
26
25
26
28
32
36
38
38
39
Net Income, GAAP
38
69
-5
38
69
46
90
114
131
-50
134
222
236
Effective Tax Rate (%)
28.14
20.7
- -
23.52
16.85
20.15
4.39
9.34
11.16
192.12
24.15
- -
0.45
Profit Margin (%)
11.52
12.96
-1.14
7.54
11.68
7.47
12.29
12.59
12.55
-5.3
13.11
18.15
17.29
Working Capital
189
228
237
131
242
215
441
484
583
596
600
735
800
LT Debt
113
159
242
123
211
163
298
297
324
336
312
444
446
Total Equity
330
380
376
406
456
492
561
641
736
689
756
797
827
Return on Invested Capital (%)
- -
13.42
- -
7.22
11.17
7.57
11.3
12.81
14.35
-6.52
12.43
- -
20.44
Return on Capital (%)
- -
13.29
- -
7
11.35
7.64
11.92
13.32
15.09
-7.44
14.01
- -
22.74
Return on Common Equity (%)
- -
19.48
-1.38
9.74
15.98
9.76
17.04
18.96
18.97
-7.01
18.58
28.63
31.81

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
60
66
73
LT Borrowings
437
454
440
LT Finance Leases
6
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
1,231
1,501
1,532

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,023
1,098
1,107
Cash, Cash Equivalents & STI
251
401
369
Accounts Receivable, Net
430
317
327
Inventories
304
335
365
Total Current Liabilities
288
317
306
Payables & Accruals
- -
- -
- -
ST Debt
60
66
73
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.89%
7.57%
5.35%
Free Cash Flow
172.71%
62.77%
79.88%
Net Income, GAAP
-119.76%
-79.97%
65.5%
Sales/Revenue/Turnover
9.35%
11.55%
19.54%
Total Cash Common Dividend
- -
51.6%
92.65%

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
178
217
283
347
1,025
2025
190
259
357
420
1,225
2026
250
339
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.31
0.77
1.17
2.5
2025
0.04
0.45
1.02
2.63
4.13
2026
0.4
0.35
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.34
2025
2.23
-1.58
- -
- -
0.65
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kleber Cesar Silveira Gomes
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cravinhos Brazil
IPO Date
Oct 21, 2014
Website
ourofino.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ouro Fino Saúde Animal Participações S.A., commercially known as Ourofino Saúde Animal, is a Brazil-based veterinary pharmaceutical company engaged in the research, development, manufacturing, and commercialization of animal health solutions, including veterinary pharmaceuticals, biologicals, and health supplements. Founded in 1987 and headquartered in Cravinhos, São Paulo, Brazil, the company operates primarily across two commercial business segments: Production Animals and Companion Animals. The Production Animals segment serves beef and dairy cattle, swine, poultry, and equine producers; its product portfolio encompasses antiparasitics, endectocides, and ectoparasiticides; reproductive hormones and fixed-time artificial insemination protocol products under the Sincro line; antimicrobials and injectable antibiotics; intramammary formulations for bovine mastitis control; anti-inflammatories and analgesics; biological solutions, including vaccines against clostridial infections, reproductive syndromes, and respiratory complexes; and metabolic stimulants, vitamins, and therapeutic feed supplements. The Companion Animals segment serves veterinary clinics, hospitals, and pet retail channels; its product offering includes oral and topical antiparasitics and ectoparasiticides under brands such as Leevre, Defend Pro, and Top Dog; dermatological solutions and therapeutic dermatocosmetics; otological treatments; veterinary antibiotics and analgesics; and specialized nutraceuticals. Ourofino operates an advanced industrial complex in Cravinhos comprising dedicated facilities for pharmaceuticals, beta-lactam manufacturing, and biological vaccine production. Geographically, the company distributes its products nationwide across Brazil and exports to international markets throughout Latin America, maintaining dedicated commercial subsidiaries in Mexico and Colombia. In recent strategic developments, Ourofino strengthened its global footprint and capital structure through a strategic partnership and equity investment by Japanese trading conglomerate Mitsui & Co., Ltd., intended to accelerate overseas market access, supply chain synergies, and cross-border commercialization. The company has also advanced its operational modernization, launched updated reproductive biotechnologies and biological formulations, and expanded its veterinary pharmaceutical portfolio across Latin American distribution networks.